🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Delighted to share our AHA Science Scientific Statement on Direct-to-Consumer Genetic Testing for Cardiovascular Disease! ahajournals.org/doi/10.1161/CI… Circulation [1/3]

Semaglutide in obesity-related #HFpEF and type 2 diabetes across baseline A1c levels (STEP-HFpEF DM) thelancet.com/journals/landi…

Delighted to share our article on hypertension treatment and orthostatic hypertension. bmj.com/content/388/bm…

Terrific work from Iftikhar J. Kullo. *10y* fu MI-GENES trial (ahajournals.org/doi/10.1161/CI… Circulation) now shows that CAD PRS disclosure vs not on top of clinical risk disclosure for intermediate risk adults leads to reduction in MACE ahajournals.org/doi/10.1161/CI… Circulation: Genomic and Precision Medicine #ACC25 Small trial

For patients with uncontrolled #Hypertension, investigational drug lorundrostat found to significantly lower blood pressure in ADVANCE-HTN trial, led by Luke J. Laffin of @clevelandClinic #ACC25. bit.ly/3Y0OJ6D

5⃣Using human genetics to predict the effects of combined APOC3, PCSK9 & HMGCR LDL-lowering therapies In a factorial Mendelian randomization, combined exposure to APOC3 and other LDL-C–lowering variants was associated with additive reductions in cardiovascular risk

SMART-CHOICE 3 results presented at #ACC25

Proud to be part of the Global Cardiovascular Disease Risk Consortium - paper just out on lifetime gain. We found that the two risk factors that impacted lifetime the most, were high blood pressure and smoking. nejm.org/doi/pdf/10.105…

Privileged to contribute to International Society of Hypertension article on "Harnessing demographic diversity in hypertension research and trials" ish-world.com/documents/ISH%… Many ongoing efforts incl. OurHealth NIH NHLBI MOSAAIC AllofUsResearch Michael Honigberg, MD, MPP's AHA Science Pressure Check study Mass General Heart

Our latest on 🫀 health, 🧬, & 🤰 now out in JACC Journals #JACC ⬆️ 1st-trimester CV health strongly associates w/ ⬇️ risk of hypertensive disorders of 🤰 (HDP) overall & across levels of HDP 🧬 risk ➡️ opp to prevent 🤰 complications & long-term CVD jacc.org/doi/10.1016/j.…

Aldosterone-targeted therapies: early implementation in resistant hypertension and CKD Both achieving BP control and mitigating the risk of aldosterone-related adverse events are cornerstones in the management of patients with TRH and CKD academic.oup.com/eurheartj/adva…

Insightful reads on genetics, omics, and precision medicine this week🧬 1⃣A model of predictive biomarker discovery for precision medicine A novel contrastive learning approach identifies biomarkers predictive of treatment response using multimodal data from early-phase

#GDMT has now arrived for #HFpEF #SGLT2i (class I) and #nsMRA (class IIa) recommendations in initial global guidelines jstage.jst.go.jp/article/circj/… #HeartFailure2025

No evidence that low diastolic blood pressure modifies benefits from hypertension treatment. Baseline Diastolic BP and BP-Lowering Effects on... : Journal of the American Society of Nephrology journals.lww.com/jasn/abstract/…

Among those with SBP >150 mmHg on indapamide, amlodipine, or olmesartan, the addition of zilbesiran (angiotensinogen siRNA) v placebo led to -12.1, -9.7, and -4.5 mmHg 24h mean ambulatory SBP change at 3mo. Increased rates of hyperkalemia, hypotension, and AKI.